An assessment of the impact of dexmedetomidine on opioid use in a neonatal intensive care unit

J Matern Fetal Neonatal Med. 2022 Aug;35(15):2836-2842. doi: 10.1080/14767058.2020.1803263. Epub 2020 Aug 12.

Abstract

Objective: To evaluate the impact of dexmedetomidine on opioid use in neonates.

Methods: A retrospective chart review of neonates that received dexmedetomidine compared to matched historical controls in a surgical tertiary NICU. The primary endpoint was overall opioid exposure. Secondary endpoints included the duration of regular opioid use, duration of opioid wean, duration of mechanical ventilation, and time to achieve full enteral feeds.

Results: There were no statistically significant differences in opioid exposure (60.3 vs 42.6 mcg ME/kg, p = .25), duration (583 vs 340 h, p = .07), or wean duration (261 vs 147 h, p = .12) between the two cohorts. In fact, these parameters showed clinically, if not statistically, significant increases in the dexmedetomidine cohort. Opioid exposure per day, length of NICU stay, duration of mechanical ventilation, and days to full enteral feeds did not differ between cohorts.

Conclusion: This retrospective cohort study did not show reduced opioid exposure in surgical neonates receiving dexmedetomidine, which is in contrast to other literature. It highlights the limitations of using a medication without appropriate guidance and assessment tools to support its use.

Keywords: NICU; Neonate; clonidine; dexmedetomidine; opioid exposure; opioids.

MeSH terms

  • Analgesics, Opioid / adverse effects
  • Dexmedetomidine* / adverse effects
  • Humans
  • Hypnotics and Sedatives / adverse effects
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Opioid-Related Disorders* / drug therapy
  • Respiration, Artificial
  • Retrospective Studies

Substances

  • Analgesics, Opioid
  • Hypnotics and Sedatives
  • Dexmedetomidine